Agenus reports 72% complete pathologic response rate in Phase 2 colon cancer trial of BOT+BAL

• Agenus reported early Phase 2 NEOASIS results showing most patients with locally advanced dMMR colon cancer had no cancer remaining at surgery.
• The six-week preoperative botensilimab and balstilimab regimen met the study’s primary endpoint.
• Results were presented at the ESMO Congress in Madrid on October 25, 2026.
• Immune-related side effects were mostly mild or moderate and manageable; one patient’s severe colitis resolved with treatment.
• Investigators are enrolling a rectal cancer cohort to assess whether the combination can help patients avoid surgery.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261025332881) on October 25, 2026, and is solely responsible for the information contained therein.